Claude H. Organ, Jr. Honorary Lectureship. Glutamine, cancer, and its therapy.
Level 5 - mechanism / opinion, no new human data
Narrative review and published lecture summarizing preclinical and preliminary human data without systematic search methods.
PubMed 8942537 · doi:10.1016/s0002-9610(96)00217-6
What was done
This paper is an honorary lecture and narrative overview summarizing in vitro, in vivo animal, and preliminary human data concerning glutamine metabolism, tumor growth, and the effects of glutamine supplementation in tumor-bearing hosts undergoing chemotherapy or radiation therapy.
What was found
The abstract reports no quantitative data, sample sizes, effect sizes, or statistical values. It reports qualitatively that while tumors can act as a glutamine trap causing host cachexia, in vivo evidence suggests supplemental glutamine does not increase tumor growth, may reduce growth via immune stimulation, and protects the host while improving therapeutic selectivity during radiation or chemotherapy.
Why it matters
The overview challenges the theoretical concern that exogenous glutamine necessarily drives tumor progression, supporting the rationale for formal clinical evaluation in oncology nutrition.
Limits
The publication is an unsystematic narrative lecture without formal synthesis methodology or reported quantitative metrics. Many of the cited observations derive from in vitro or animal models, and clinical safety and efficacy in humans were unproven at the time of writing.
Cited by
- supports Cancer cachexia occurs when tumor cells mobilize and consume glutamine by breaking down host skeletal muscle.